Aktis Oncology, Inc.

Aktis Oncology, Inc. が 2026年8月13日 に発表した内容

企業自身の 8-K から。

経営陣の発言

“This was a quarter of strong execution for Aktis, focused on generating clinical data and building infrastructure to support our clinical pipeline,”

発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。

株価の反応

発表は引け後か寄り前に出るため、ここでの値動きは次の取引日のものです。

Aktis Oncology, Inc. の事業内容

Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anticancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end clinical supply chain built for resiliency and scalability, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

発表資料の末尾に記載された、企業自身による説明です。